![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, May 24, 2016 11:45:44 AM
In ph 3 of apremilast, only 33% of those being treated reached the endpoint, which was actually below the best result they saw in one of their multiple phase II trials (41%). Some of the lower doses barely outdid placebo, and none of them ever really exceeded a 29% response rate.
If you contrast the CTIX results to this, I think it is actually quite promising. First, there were no real SAE's, which is important because of the difficulty of using biologics; this is why Otezla sells at all in the first place. Second, its efficacy (either 35% or 43.7%, depending on which data you like to use) was at the very least comparable to Otezla. I usually am wary of cherry-picking subset data, but the wide range in dosing in Prurisol indicates to me that the management genuinely did not know what range would be effective or not, and likely preferred to err on side of caution, as the worst thing for them would be to witness high rates of dropouts due to SAE's.
I think it is also of note that the placebo leg in CTIX's trial had an abnormally high rate of efficacy (16.7%) vs. those of the Celgene trials, all of which were in the 5-10%. Perhaps this could be attributed to randomness and if that # decreased in a Ph.3, that could make the trial look even more appealing.
All this to say, I doubt that CTIX will be able to prove superiority of Prurisol to Otezla based on these study results. HOWEVER, I do believe that the drug has shown efficacy, certainly enough to warrant a Ph. 3 trial, and likely enough to become a serious competitor to Otezla in what is a pretty huge market. Pretty good for a compound most considered an after-thought compared to Kevetrin and Brilacidin.
http://www.ncbi.nlm.nih.gov/pubmed/26089047
http://www.ncbi.nlm.nih.gov/pubmed/22748702
http://www.ncbi.nlm.nih.gov/pubmed/23030767
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM